XBI - IBB And XBI: 4 Reasons To Buy Biotech Stocks Ahead Of 2022

• Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms.
• Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand.
• It's very likely that M&A activity will start accelerating soon, with big pharma players needing and wishing to boost what is otherwise relatively mediocre growth.
• If history is any indication, there are very good reasons to believe that 2022 would be a positive year for biotechs.

For further details see: